nodes following infectious challenges, the role of tissue-resident neutrophils in physiological settings is less clear. We hypothesise that neutrophils are present within lymph nodes and can influence adaptive immunity under physiological conditions. Methods Lymph nodes from unchallenged C57BL/6 and LysM-GFP mice were harvested; single cell suspensions were generated for flow cytometric analysis, and frozen sections stained for confocal microscopy. Two-photon intravital imaging of popliteal lymph nodes was performed to examine neutrophil dynamic behaviour in vivo. Human lymph nodes were harvested from organ donors and analysed by flow cytometry and mass cytometry. Results Neutrophils were present in lymph nodes in mice without prior inflammatory or infectious challenge. Whilst some neutrophils were within blood vessels (11% in inguinal lymph node, 10% in popliteal lymph node, 12% in mesenteric lymph node) or lymphatic vessels (15% in inguinal lymph node, 21% in popliteal lymph node, 18% in mesenteric lymph node), the majority were located in lymph node tissues. Lymph node neutrophils showed higher surface expression of major histocompatibility complex II (MHCII) compared to blood, bone marrow and splenic neutrophils ( figure 1A ). In vivo, neutrophils were capable of immune complex uptake, and their dynamic behaviour differed according to their location within the lymph node. Neutrophils were also present in human lymph nodes, and expressed surface MHCII (figure 1B). Immune cell profiles of matched lymph nodes and spleen were compared using mass cytometry. Isolated human blood neutrophils upregulated surface MHCII upon ex vivo immune complex stimulation. Conclusion We have demonstrated the presence of tissue-resident neutrophils within murine and human lymph nodes, and their capacity to express MHCII, potentially influencing the adaptive immune response via antigen presentation. Introduction and Objectives Chronic Lung Allograft Dysfunction (CLAD) is a major limiting factor to survival post-lung transplant (LTx), restricting 5 year survival to approximately 55%. The mechanism by which CLAD and its sub-types occur are not fully understood and changes in the microbiota may play a role in the development of this condition. Moreover, azithromycin prolongs CLAD-free post-transplantation. This study aims to determine the effect of azithromycin over time on the airway microbiota post-LTx and how the microbiota changes with the development of CLAD. Methods As part of a double-blind RCT in UZ Gasthuisberg, Leuven, Belgium, 1 patients undergoing LTx were previously randomised to receive either azithromycin (n=43; 250 mg three times per week) or placebo (n=40) treatment following discharge post-transplant. Regular routine bronchoscopy was carried out on all patients and bronchoalveolar lavage (BAL) samples from discharge, 12, 24 months and at diagnosis of suspected rejection were processed for microbiota analysis using 16S Illumina sequencing and 16S quantitative PCR. Results To date, 42 azithromycin treated (n=17 patients) and 52 (n=22 patients) placebo samples have been analysed. Microbiota diversity was significantly higher (p=0.0467) in the azithromycin group compared to placebo. Furthermore, a trend for reduced dominance by Pseudomonas, with re-emergence of taxa considered to constitute a 'healthy' microbiota (e.g., Prevotella, Veillonella, Streptococcus) was observed. There were no significant differences in 16S copies per mL BAL between the two groups. Eight samples (n=5 azithromyin, n=3 placebo) at suspected rejection have also been analysed. The azithromycin group exhibited low relative abundances of Pseudomonas (mean 7.7%), while the placebo group showed dominance by this taxa (mean 84.87%). Conclusions Restoration of a diverse microbiota, while preventing dominance by Pseudomonas, may be a factor contributing towards the prophylactic effects of azithromycin observed in LTx patients 1 . Further analysis of microbiota data alongside clinical data e.g., development of CLAD, CLAD-free survival time, etc. is ongoing. 
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